Vaxcyte, Inc.
PCVXNASDAQHealthcare● Active
$46.33
$-1.03(-2.17%)
Market Cap$6.7B
P/E Ratio—
52W High$65
52W Low$29.08
Vaxcyte, Inc. (PCVX) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · PCVX · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.77B) | ($0.46B) | ($0.40B) | ($0.22B) | ($0.10B) |
| Depreciation & Amort. | $0.02B | $0.02B | $0.01B | $0.01B | $0.00B |
| Stock-Based Comp. | $0.14B | $0.08B | $0.05B | $0.02B | $0.01B |
| Change in Working Capital | $0.02B | ($0.05B) | $0.08B | $0.01B | ($0.04B) |
| Net Cash from Operations | ($0.66B) | ($0.45B) | ($0.30B) | ($0.17B) | ($0.12B) |
| Investing Activities | |||||
| Capital Expenditure | ($0.01B) | ($0.02B) | ($0.07B) | ($0.01B) | ($0.01B) |
| Purchases of Investments | ($1.21B) | ($3.09B) | ($1.33B) | ($0.10B) | ($0.34B) |
| Sales of Investments | $1.71B | $1.20B | $0.62B | $0.18B | $0.13B |
| Net Cash from Investing | $0.44B | ($2.01B) | ($0.77B) | $0.07B | ($0.21B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Cash from Financing | $0.00B | $2.45B | $0.64B | $0.86B | $0.02B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.67B) | ($0.48B) | ($0.36B) | ($0.18B) | ($0.13B) |
| FCF Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Vaxcyte, Inc. data
About Vaxcyte, Inc. (PCVX) Cash Flow Statement
Vaxcyte, Inc. generated operating cash flow of ($0.66B) and free cash flow of ($0.67B) for 2025 — a FCF margin of —. Capital expenditure was ($0.01B).
Frequently asked questions
PCVX · 4 questionsVaxcyte, Inc. generated free cash flow of ($0.67B) for 2025, down 40.9% year-over-year.
PCVX free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10